Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

10/15/2025

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Erythromycin Ebb

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Erytromycin Testmiljö

Erytromycin

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Källén B, Danielsson BR. Fetal safety of erythromycin An update of Swedish data. Eur J Clin Pharmacol. 2014;70:355-60.

  2. Källén BA, Otterblad Olausson P, Danielsson BR. Is erythromycin therapy teratogenic in humans?. Reprod Toxicol 2005;20:209-14.

  3. Andersson NW, Olsen RH, Andersen JT. Association between use of macrolides in pregnancy and risk of major birth defects: nationwide, register based cohort study. BMJ. 2021;372(0):n107.

  4. Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. Am J Obstet Gynecol. 2019;221(6):648e1-648e15.

  5. Bérard A, Sheehy O, Zhao JP, Nordeng H. Use of macrolides during pregnancy and the risk of birth defects: a population-based study. Pharmacoepidemiol Drug Saf. 2015;24:1241-8.

  6. Romøren M, Lindbæk M, Nordeng H. Pregnancy outcome after gestational exposure to erythromycin - a population-based register study from Norway. Br J Clin Pharmacol. 2012;74:1053-62.

  7. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A population-based case-control teratologic study of oral erythromycin treatment during pregnancy. Reprod Toxicol 1999;13:531-6.

  8. Fan H, Gilbert R, O'Callaghan F, Li L. Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. BMJ. 2020;368(0):m331.

  9. Lund M, Pasternak B, Davidsen RB, Feenstra B, Krogh C, Diaz LJ et al. Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study. BMJ. 2014;348:g1908.

  10. Cooper WO, Griffin MR, Arbogast P et al. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med 2002;156:647-50.

  11. Cooper WO, Ray WA, Griffin MR. Prenatal prescription of macrolide antibiotics and infantile hypertrophic pyloric stenosis. Obstet Gynecol 2002;100:101-6.

  12. Lin KJ, Mitchell AA, Yau WP, Louik C, Hernández-Díaz S. Safety of macrolides during pregnancy. Am J Obstet Gynecol. 2013;208:221e1-8.

  13. Bahat Dinur A, Koren G, Matok I, Wiznitzer A, Uziel E, Gorodischer R et al. Fetal safety of macrolides. Antimicrob Agents Chemother. 2013;57:3307-11.

  1. Källén B, Danielsson BR. Fetal safety of erythromycin An update of Swedish data. Eur J Clin Pharmacol. 2014;70:355-60.
  2. Källén BA, Otterblad Olausson P, Danielsson BR. Is erythromycin therapy teratogenic in humans?. Reprod Toxicol 2005;20:209-14.
  3. Andersson NW, Olsen RH, Andersen JT. Association between use of macrolides in pregnancy and risk of major birth defects: nationwide, register based cohort study. BMJ. 2021;372(0):n107.
  4. Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. Am J Obstet Gynecol. 2019;221(6):648e1-648e15.
  5. Bérard A, Sheehy O, Zhao JP, Nordeng H. Use of macrolides during pregnancy and the risk of birth defects: a population-based study. Pharmacoepidemiol Drug Saf. 2015;24:1241-8.
  6. Romøren M, Lindbæk M, Nordeng H. Pregnancy outcome after gestational exposure to erythromycin - a population-based register study from Norway. Br J Clin Pharmacol. 2012;74:1053-62.
  7. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A population-based case-control teratologic study of oral erythromycin treatment during pregnancy. Reprod Toxicol 1999;13:531-6.
  8. Fan H, Gilbert R, O'Callaghan F, Li L. Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. BMJ. 2020;368(0):m331.
  9. Lund M, Pasternak B, Davidsen RB, Feenstra B, Krogh C, Diaz LJ et al. Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study. BMJ. 2014;348:g1908.
  10. Cooper WO, Griffin MR, Arbogast P et al. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med 2002;156:647-50.
  11. Cooper WO, Ray WA, Griffin MR. Prenatal prescription of macrolide antibiotics and infantile hypertrophic pyloric stenosis. Obstet Gynecol 2002;100:101-6.
  12. Lin KJ, Mitchell AA, Yau WP, Louik C, Hernández-Díaz S. Safety of macrolides during pregnancy. Am J Obstet Gynecol. 2013;208:221e1-8.
  13. Bahat Dinur A, Koren G, Matok I, Wiznitzer A, Uziel E, Gorodischer R et al. Fetal safety of macrolides. Antimicrob Agents Chemother. 2013;57:3307-11.